A New Method to Determine Alzheimer's and Parkinson's Toxins in the Lipid-Riched Environment
About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
September 01, 2020 - August 31, 2022
Grant ID
A20201759S
Goals
In diseases such as Alzheimer’s and Parkinson’s, toxic protein lumps form holes in them nerve cells. I want to discover how those lumps assemble at atomic resolution.
Summary
In Alzheimer’s disease, Aβ peptides form toxic and transient oligomers, leading to cellular membrane leakage and then neuronal cell death. We aim to stabilize the transient oligomers on a functionally relevant α-hemolysin (αHL) scaffold and confine the stabilized/hybridized oligomers for crystallization in the lipidic cubic phase system followed by X-ray structure determination. The hybridized Aβ oligomers will allow studying many of the features of amyloid oligomers that can not be characterized due to the transient and heterogeneity of wild-type Aβ oligomers. Our work will yield essential insight into the mechanism of its neurotoxicity.
Grants
Related Grants
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Alzheimer's Disease Research
Regulatory mechanisms underlying endosomal targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Olav Andersen, PhD
Regulatory mechanisms underlying endosomal targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Olav Andersen, PhD
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD